formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, irbesartan avapro achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide, irbesartan avapro and Avapro HCT.[edit].

& PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonist used irbesartan avapro for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the treatment of hypertension. Irbesartan was developed by irbesartan avapro Research (now part of sanofi-aventis). irbesartan avapro is jointly marketed irbesartan avapro sanofi-aventis and irbesartan avapro Squibb under the trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ irbesartan avapro irbesartan avapro Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due with.

APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism.